Cost-utility and Biological Underpinnings of MBSR in Fibromyalgia Syndrome

• Status: Completed
• Trial end date: 2018-12-31
• Target enrollment: 0
• Participant gender: All

Summary

Purpose:

Fibromyalgia syndrome (FMS) is a disabling condition mainly characterized by chronic widespread pain, disturbed sleep, fatigue, and distress. The estimated overall prevalence of FMS in Europe is 2.9% and it incurs in high personal, social and healthcare costs. Available treatments in FMS are not curative and there is some evidence of positive effects of mindfulness-based stress reduction (MBSR) in patients with chronic pain and FMS. Nevertheless, although promising, the positive findings obtained in previous studies implementing mindfulness-based interventions in patients with FMS have to be interpreted with caution due to important methodological limitations (e.g. absence of randomization, high attrition rates, or small sample sizes). Therefore, further research in larger studies using more adequate methodologies is warranted. Furthermore, little is known about putative neurobiological processes underpinning the effects of mindfulness training in patients with chronic pain.

Aims: The aim of this randomized, controlled trial (RCT) is two-fold: firstly, to assess the effectiveness and cost-utility of MBSR added to treatment as usual (TAU); and secondly, to evaluate the effects of the compared interventions on neurobiological parameters. Specifically, MBSR will be compared to an active control which was previously reported as a cost-effective intervention (TAU + FibroQol psycho-educational program; Luciano et al., 2013) and also vs. TAU alone (in a 12-month follow-up RCT). Brain structure and function of pain-relevant areas and levels of inflammation markers (cytokines) will be assessed pre-post interventions in half of the study participants.

Methods:

Design: RCT with three arms:

1. TAU + MBSR,

2. TAU + FibroQoL and

3. TAU.

Sample: 180 adults with FMS according to the ACR 1990 criteria (N=60 for each study arm) will be recruited from from the Parc Sanitari Sant Joan de Déu Rheumatology Service, Sant Boi de Llobregat, Spain. Half of the participants will be randomly selected to participate in the neurobiological pre-post evaluation (N= 30 each group). All patients will be assessed at baseline, post-intervention and 12-month follow-up for clinical variables, prep-post intervention for biomarkers study, and baseline and 12-month follow-up for cost-related variables.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Fundació Sant Joan de Déu
• Collaborators: Carlos III Health Institute; Parc Sanitari Sant Joan de Déu; Preventive Services and Health Promotion Research Network

Criteria

General Inclusion Criteria:

• Patients of both genders between 18-65 years old.

• Verified diagnosis of FMS according to the American College of Rheumatology criteria (ACR 1990).

• Ability to understand Spanish language.

• Written informed consent.

General Exclusion Criteria:

• Participation in other clinical trials

• Cognitive impairment according to MINI (total score ≤ 24)

• Receiving psychological treatment during the last or the current year

• Previous experience with meditation or mind-body therapies.

• Physical/psychiatric comorbidity that interferes with treatment (any severe medical illness, psychotic symptoms, substance abuse).

• Not being able to attend to group sessions.

• Being involved in ongoing litigation relating to the FMS.

Additional Inclusion Criteria for the biomarkers sub-study (90 participants in total):

• Female gender

• Right-handed

Additional Exclusion Criteria for the biomarkers sub-study:

• Neoplastic illnesses (diagnosed from the medical history), infection, cardiopulmonary, vascular or other internal medical conditions

• Use of oral or local corticosteroids or anti-cytokine therapy

• Needle-phobia

• Impossibility of being scanned in MRI (due to agoraphobia, metal implants, pace-marker…)

• BMI> 36kg/m2 or >110Kg

• Consuming > 8 caffeine units per day

• Smoking > 5 cigarettes per day

• Acute pain not related to the FMS at the day of biomarkers evaluation

• Being pregnant or breastfeeding.